CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Nov 14, 2022 4:05pm EST
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Nov 02, 2022 8:45am EDT
CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run Oct 10, 2022 9:00am EDT
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM Oct 07, 2022 8:00am EDT
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Sep 28, 2022 9:05am EDT
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Sep 23, 2022 9:00am EDT
CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep 07, 2022 8:45am EDT
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Aug 15, 2022 8:05am EDT
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022 Jul 25, 2022 8:05am EDT
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Jun 23, 2022 8:35am EDT
